What a Safe GLP-1 Telehealth Follow-Up Includes (2026 Checklist)

By the WPG Editorial Team · Last verified: May 18, 2026 · Next review: August 2026

The short answer

A safe GLP-1 telehealth follow-up includes nine specific things: a real prescriber whose license you can look up, a clinical check-in (not just a form), side-effect screening that names the actual red flags, a documented dose decision, risk-based labs, weight and muscle tracking, a lifestyle review, a clear urgent-symptom plan, and a discontinuation plan. During the early dose-changing phase, you should hear from a clinician every 2 to 4 weeks. Once stable, every 3 months is the minimum.

Heads up — this page is not medical advice. It’s a patient-facing checklist built from FDA labels, major clinical guidelines, and state telehealth rules. If you have severe stomach pain, can’t keep fluids down, see yellow in your eyes, feel a lump in your neck, or are having an allergic reaction, stop reading and call your provider or go to urgent care.

What a safe GLP-1 telehealth follow-up includes: the 9 elements at a glance

A safe GLP-1 telehealth follow-up is built around nine things. The first four are the floor. If your program skips any of them, that’s not “telehealth being convenient” — that’s care being lowered.

#	Element	During dose changes	On maintenance
1	An identifiable, licensed prescriber	Named at every dose change	Named at every visit
2	A real clinical check-in (not just a form)	Every 2–4 weeks	Every 3 months minimum
3	Side-effect screen including pancreatitis, gallbladder, and thyroid red flags	Every visit	Every visit
4	A documented dose decision (continue, hold, raise, lower)	At every titration step	At every maintenance review
5	Risk-based labs (A1C if diabetic; kidney panel if severe GI symptoms; others by clinical situation)	Baseline + repeat by risk	A1C every 3–6 months if relevant; others as indicated
6	Weight and body composition (the muscle question)	Reviewed every visit	Reviewed every visit
7	Lifestyle review (protein, strength training, sleep, mood, eating patterns)	Every other visit	Every visit
8	A clear urgent-symptom protocol	Confirmed at start	Reviewed if symptoms come up
9	A stop / pause / restart plan	Reviewed at maintenance	At least once a year

The fast self-check: If you’ve been on a GLP-1 for more than 3 months and you can’t answer “yes” to elements 1, 2, 3, and 4, your follow-up isn’t meeting the bar. We’ll show you exactly how to fix that further down.

Why follow-up is the part of GLP-1 telehealth that breaks down most often

Follow-up is where GLP-1 telehealth most often fails. On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products — and said it had sent thousands of warning letters to pharmaceutical and telehealth firms across the prior six months.

Major clinical groups — the Obesity Medicine Association, the American Diabetes Association, the Endocrine Society — say telehealth can deliver good GLP-1 care. The Obesity Medicine Association is explicit: remote prescribing must not lower the standard of care. The medium changed. The medicine didn’t.

What changed is that some platforms are built around volume, not care. You might see a different prescriber name every visit and feel like nobody knows you. That’s the gap this checklist is built to close. The question isn’t “is telehealth safe?” The question is: does your specific follow-up include the nine things below?

An identifiable, licensed prescriber

A safe follow-up starts with a real clinician you can name and verify. Your prescriber should have a name, a license type (MD, DO, NP, or PA), and an active license in your state — and you should be able to look them up on your state medical board’s website in under two minutes.

How to check in under two minutes

Find your prescriber’s name (in your portal, on your prescription label, or in a visit note).
Search “[your state] medical board license lookup” in any search engine.
Type the prescriber’s name into the state’s official portal.
Confirm they have an active license, in good standing, in your state.

State rules verified for 2026

State	What’s verified	What it affects	Verified
Florida	Re-evaluation at least every 3 months for anti-obesity-drug patients (Florida Administrative Code Rule 64B15-14.004)	Minimum follow-up cadence	May 2026
Mississippi	Guidance restricts off-label peptide-based weight-loss prescribing and warns against compounded semaglutide use outside the approved pathway	Compounded and off-label paths	May 2026
Virginia	Previously cited rule 18VAC85-50-181 is marked repealed effective July 17, 2025. Do not rely on it as current.	Was monthly follow-up; now no specific rule	May 2026

If your state isn’t here, search your state medical board’s website directly. Don’t trust a telehealth platform’s interpretation of your state’s rules — verify at the source.

A real clinical check-in — not just a form

Asynchronous follow-up can be safe when a real licensed clinician is actually reviewing your information, not an auto-approval. A form that gets approved the same minute you submit it isn’t a clinical check-in. It’s a vending machine.

✓ What a real check-in looks like

A licensed clinician (not a bot) reviews your responses
The response addresses your specific situation, not a copy-paste template
You can request a synchronous video or phone visit when something is unclear or urgent
There’s a documented response time, and someone hits it

✗ What it doesn’t look like

You hit submit and your next prescription is approved within seconds
You report a new symptom and get a templated “thanks for letting us know”
The only path to a real clinician is to leave the platform
Every interaction is with a different person who hasn’t read your prior notes

If you’ve been on a GLP-1 for more than two months and you can’t point to a single clinical exchange where a real human responded to something specific in your case, that’s element 2 failing.

Side-effect screening — including the red flags that aren’t just nausea

Every GLP-1 follow-up should ask about gut symptoms — and specifically screen for the three red-flag categories on the FDA label: pancreatitis (sudden severe stomach pain, often spreading to the back), gallbladder disease (right-upper-belly pain, fever, yellowing of skin or eyes), and thyroid C-cell tumor symptoms (a lump in the neck, persistent hoarseness, trouble swallowing or breathing).

The red-flag translation table

Red flag in FDA labeling	Plain-English patient wording	What your follow-up should ask	When to skip the portal
Acute pancreatitis	Severe, lasting belly pain that may spread to your back, often with nausea or vomiting that won't quit	"Any severe stomach pain that doesn't go away, especially pain that wraps around to your back?"	Call urgent number or go to urgent care immediately
Acute gallbladder disease	Sharp pain in the upper-right belly, fever, yellowing of skin or eyes	"Any pain in your upper right side, fever with belly pain, or yellowing of your eyes or skin?"	ER for severe pain, fever, jaundice, or rapid worsening
Thyroid C-cell tumor symptoms	A new lump in your neck, lasting hoarseness, trouble swallowing or breathing	"Any new lump in your neck, voice changes that won't go away, or trouble swallowing?"	Same-day call to provider; ER if breathing is affected
Severe hypersensitivity / allergic reaction	Throat swelling, trouble breathing, full-body hives	"Any reaction at the injection site or full-body that worried you?"	911 or ER for breathing or throat involvement
Severe GI symptoms with dehydration	Vomiting or diarrhea you can't keep fluids down for	"Are you keeping fluids down? How many trips to the bathroom?"	Urgent care if dehydrated, can't keep water down, or feel faint

Pancreatitis red flags in more detail

Pancreatitis pain is different from typical GLP-1 nausea: severe, persistent upper-belly pain that may radiate to your back, often with nausea or vomiting that doesn’t quit. The FDA labels for Wegovy and Zepbound both tell patients to stop the medication and contact a provider if pancreatitis is suspected. Don’t wait for your next scheduled check-in. Call.

Gallbladder red flags in more detail

Rapid weight loss raises the risk of gallstones, and GLP-1 medications can make this more likely. The Zepbound label says suspected cholecystitis (an inflamed gallbladder) needs diagnostic studies and clinical follow-up. Severe right-upper-belly pain, fever, jaundice, or anything rapidly worsening is not a portal-message situation.

Thyroid C-cell tumor red flags in more detail

The FDA labels for all semaglutide products (Wegovy, Ozempic, Rybelsus) and tirzepatide products (Zepbound, Mounjaro) carry a boxed warning — the strongest FDA warning — about thyroid C-cell tumors. These medications are also contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). If your intake never asked about either, that’s a serious gap.

A documented dose decision

Your dose isn’t supposed to go up on a calendar. It’s supposed to go up when the minimum interval has passed under the FDA-approved label, and when you’re tolerating the current dose. An auto-escalation is the most common quiet failure of unsafe care.

FDA-approved dose schedules (verified May 2026)

Medication	Form	Starting dose	Escalation interval	Max / maintenance
Wegovy injection	Weekly subcutaneous	0.25 mg	Every 4 weeks (minimum)	1.7 mg or 2.4 mg adult maintenance; up to 7.2 mg if more reduction needed after 4 weeks at 2.4 mg
Wegovy tablets	Daily oral	1.5 mg (days 1–30)	30-day steps: 4 mg, 9 mg, 25 mg	25 mg once daily
Zepbound	Weekly subcutaneous	2.5 mg	At least every 4 weeks, in 2.5 mg increments	Up to 15 mg weekly
Ozempic	Weekly subcutaneous	0.25 mg	At least every 4 weeks	Up to 2.0 mg weekly (type 2 diabetes)
Mounjaro	Weekly subcutaneous	2.5 mg	At least every 4 weeks, in 2.5 mg increments	Up to 15 mg weekly (type 2 diabetes)
Foundayo (orforglipron)	Daily oral tablet	0.8 mg	2.5 mg after ≥30 days; then 5.5 mg, 9 mg, 14.5 mg, 17.2 mg — at least 30 days at each level	Based on response and tolerability; FDA-approved April 1, 2026

The dose-decision checklist your provider should run through

Has the minimum interval passed since the last dose change?
Are your side effects mild, improving, and manageable?
Have you missed any doses, and if so, how many?
Are you eating enough? Drinking enough? Keeping weight on without losing too fast?
Are you having any of the red-flag symptoms from element 3?
Have you started or stopped any other medications since your last visit?
Has anything in your medical history changed (new diagnosis, pregnancy planning, surgery on the calendar)?
Is the current dose actually producing a response (weight, A1C, appetite)?

If your provider isn’t walking through some version of those, your dose is going up by clock, not by care.

Do you need labs at every GLP-1 follow-up?

You don’t need the same labs at every visit. The ADA’s patient guidance says A1C is usually checked every 3 months if your diabetes medications have changed or your last A1C wasn’t at your target, and every 6 months once it’s at goal. “No labs ever” is the failure mode to avoid.

Labs that come up most often

A1C: Average blood sugar over 3 months. Critical if you have diabetes or prediabetes.
CMP: Kidney function, liver function, electrolytes. Important if you’ve had severe GI symptoms.
Lipid panel: GLP-1s often improve these; checking is how you find out.
TSH: Relevant if you already have a separate thyroid condition. Not the GLP-1 boxed-warning screen — the Zepbound label says routine TSH or ultrasound is of uncertain value for MTC detection.

Labs matter more when:

You have diabetes or prediabetes
You have any kidney disease history
You’ve had severe vomiting or diarrhea
You’re on insulin or a sulfonylurea
You’re losing weight very quickly
You haven’t had baseline labs in over a year
You’re switching between semaglutide and tirzepatide

Skipping labs is reasonable when:

You’re young, generally healthy, recently had a complete baseline panel
Your weight loss is gradual with only mild nausea
You’re on a stable maintenance dose

Weight tracking — and the muscle question almost nobody asks

A safe follow-up looks at your weight trend, but the better ones also ask about strength and muscle. Across all weight-loss methods, roughly 25–30% of weight lost tends to come from lean (muscle) mass. On a GLP-1 without enough protein and resistance training, that fraction can be higher.

Most follow-ups ask one question: “what’s your weight?” The better ones ask three:

What's your weight trend over the past month?

Single readings are noise; trend is signal.

How's your strength and energy?

A proxy for lean-mass loss when you can't do a DEXA scan.

Are you eating enough protein and doing any resistance training?

The 2025 joint OMA/TOS/ASN/ACLM advisory was explicit about this.

The Endocrine Society benchmark: Weight-loss medication should be continued if it’s effective and safe — defined as at least 5% weight loss at 3 months. Below 5%, the medication should be stopped and another approach considered. That 5% conversation needs to happen. If nobody’s having it, that’s a gap.

A lifestyle review — protein, training, sleep, mood

A safe GLP-1 follow-up covers more than the prescription. The 2025 joint advisory from the Obesity Medicine Association, The Obesity Society, the American Society for Nutrition, and the American College of Lifestyle Medicine is explicit: GLP-1 therapy works best with adequate protein, resistance training, regular aerobic activity, sleep, and screening for disordered eating and mental-health concerns.

What “lifestyle review” should sound like at a real follow-up:

Protein

"How much protein are you getting on a typical day?"

Strength training

"Are you doing any resistance training? How often?"

Aerobic activity

"Are you walking, biking, swimming, anything? About how much per week?"

Sleep

"How many hours are you getting? Is it good sleep or bad sleep?"

Disordered eating

"Are you ever skipping meals on purpose to lose more? Eating in ways that feel out of control?"

Mental health

"Has your mood changed since starting? Any new anxiety, depression, or thoughts that worry you?"

A follow-up that never goes past “how’s your weight?” is missing a category that determines whether the medicine actually works long-term.

What symptoms should make you call your provider — not message?

You should know — before you ever need it — exactly what to do if you get a possible pancreatitis, gallbladder, allergic reaction, or other urgent symptom. The right answer is rarely “send a portal message and wait.”

Ask yourself this question: If you woke up tonight with severe stomach pain spreading to your back, what would you do?

If your answer is “send a portal message,” your provider hasn’t built element 8. A safe follow-up tells you, in writing, which lane each situation falls into:

🚨 ER right now

Severe pain spreading to your back; can’t keep fluids down; yellowing skin or eyes; signs of an allergic reaction (throat swelling, trouble breathing, full-body hives); a new lump in your neck with breathing or swallowing changes.

📞 Call our urgent number right now

New severe right-upper belly pain; fever with belly pain; vision changes if you have diabetes; hypoglycemia symptoms (shakiness, sweating, confusion) if you take insulin. And you actually have the number saved.

💬 Portal message — we’ll respond within X hours

Mild nausea, manageable GI side effects, questions about injection technique, weight-trend questions, scheduling.

If your program doesn’t have those three buckets documented, you’re improvising in a medical emergency. That’s not safe.

What’s the plan if you stop, pause, or lose access?

GLP-1s aren’t designed as short courses for most patients — they’re long-term treatments for chronic conditions. But supply shifts, side effects, insurance changes, life events, or personal decisions can interrupt therapy. A safe follow-up has a plan for stopping, pausing, restarting, and what happens to your weight.

→Insurance changes. Coverage can vanish overnight.
→Supply disruptions. Compounded GLP-1 supply has tightened sharply since the FDA's February 6, 2026 statement and wave of warning letters.
→Pregnancy planning. The Wegovy label says to stop at least 2 months before a planned pregnancy. The Zepbound label says to discontinue when pregnancy is recognized.
→Side effects. Sometimes the math stops making sense.
→Personal choice. People decide to stop. That's allowed.

A 2025 JAMA Network Open cohort study of 125,474 adults found that 46.5% of patients with type 2 diabetes and 64.8% of patients without type 2 diabetes discontinued GLP-1 therapy within 1 year. A safe provider has thought through what to do about weight regain, supply gaps, and whether a different medication makes sense — before you need the conversation.

How often you should hear from a clinician at each stage

Safe follow-up scales to where you are in therapy. Weeks 1–4 are the highest-risk window for side effects and dropouts. The middle months are when most dose changes happen. After that, you’re in maintenance. Each stage has its own cadence.

Stage	Timing	Visit cadence	What’s covered
Initiation	Week 0	Intake + baseline review	Full medical history, contraindication review, informed consent, red-flag education, baseline labs as indicated
Early titration	Weeks 2–4	First check-in	Side-effect tolerance, injection or pill technique, early weight trend
Titration	Weeks 4–16 (sema) or 4–24 (tirz)	Every 4 weeks	Dose decisions, side effects, lifestyle reinforcement
3-month response check	Around month 3	Response evaluation	≥5% weight loss benchmark (Endocrine Society); decide to continue, switch, or stop
Maintenance	Months 4–12	Every 3 months minimum	Dose review, side effects, lifestyle, labs by risk
Long-term	Year 1+	Every 3–6 months	Long-term tolerability, periodic labs, stop/pause/restart planning

Florida’s current rule (Florida Administrative Code 64B15-14.004) requires re-evaluation at least once every 3 months for anti-obesity-drug patients. If you’re in Florida and your provider isn’t hitting that minimum, that’s a regulatory issue, not a preference.

Before any refill or dose increase, these 6 things should happen

Before a refill or dose increase, a safe follow-up confirms the exact medication and dose, screens for new or worsening side effects, asks about missed doses, reviews any new medications or medical issues, decides whether to escalate or hold, and gives you clear next steps. If your “follow-up” is a form with “what dose do you want?” — that’s not a follow-up.

Is the right medication on the right dose? Confirm name, mg, frequency, last dose, missed doses.
Are side effects improving, stable, or worse? Get specific. “Some nausea on injection day, eats normally otherwise” is different from “throwing up twice a day.”
Any red-flag symptoms in the past month? Pancreatitis, gallbladder, thyroid, allergy.
Any new medications, diagnoses, pregnancy plans, or surgeries?
Is the response adequate? Weight trend, A1C if relevant, appetite control.
Decision documented: continue, hold, raise, lower, switch, or stop.

A safe follow-up writes that decision down — and gives you a copy. If your visit ends without a clear answer to “what are we doing for the next month and why,” your provider didn’t finish the visit.

Starting GLP-1 telehealth and want a pre-enrollment checklist?

Our 15-point vetting guide walks through how to screen any GLP-1 telehealth provider before you sign up.

GLP-1 Telehealth Safety Checklist →

What makes compounded GLP-1 follow-up different

The 9-element standard is the same for compounded and FDA-approved GLP-1s. But compounded therapy adds three follow-up jobs: confirming the pharmacy and concentration on every refill, checking dosing instructions (especially when doses are given in “units” rather than mg), and having a plan for what happens if FDA enforcement or supply changes interrupt access.

FDA compounded GLP-1 enforcement — key facts

→ March 3, 2026: FDA announced 30 warning letters to telehealth companies for false or misleading compounded GLP-1 claims
→ February 6, 2026: FDA escalated enforcement on compounded semaglutide supply
→ Documented dosing errors: patients accidentally administered 5–20× more semaglutide than intended
→ Healthcare-provider miscalculations resulting in 5–10× the intended dose

The compounded GLP-1 proof table — use this every refill

What to check	Where to find it	What it should match	Why it matters
Active ingredient (e.g., semaglutide, tirzepatide)	Pharmacy label	Your prescription	Confirms you have the right molecule, not a research-use product or a different peptide
Concentration (e.g., 2.5 mg/mL, 5 mg/mL)	Vial label	Prescription instructions	A 2.5 mg/mL and 5 mg/mL vial need completely different draw volumes for the same dose
Prescribed dose in milligrams	Prescription / provider note	What you're drawing	The mg is the actual dose; units are just the volume on the syringe
Volume / units to draw	Pharmacy instructions	Match against concentration math	mg vs units confusion is one of the dosing errors the FDA has flagged with compounded semaglutide
Pharmacy name and license	Vial label / pharmacy paperwork	A state-licensed pharmacy you can verify	Verify on your state board of pharmacy website
503A or 503B classification	Pharmacy paperwork	Should be disclosed	503A is state-licensed traditional compounding; 503B is FDA-registered outsourcing facility (stricter standards)

Three compounded-specific follow-up questions, every refill:

What pharmacy is filling this? Get a name. Verify it’s a state-licensed pharmacy. Ask whether it’s 503A or 503B.
What’s the concentration on this vial or pen? Critical — the FDA has documented dosing errors where patients drew the same number of units from vials of different concentrations and got very different doses.
What’s the plan if my supply is interrupted? Regulatory enforcement can move fast.

Red flags that your GLP-1 telehealth follow-up isn’t safe

Unsafe follow-up has a recognizable pattern. The yellow flags below are worth a direct question. The red flags are reasons to switch providers. Any single yellow flag isn’t a crisis; two or more, or any single red flag, means something’s wrong.

🟡 Yellow flag (worth asking about)	🔴 Red flag (worth switching)
You can't easily find your prescriber's name in the platform	Your prescriber's name doesn't exist on your state medical board's portal
Asynchronous-only follow-up is the default	There's no synchronous option at all, even on request
Dose increases happen the same day you submit a form	Dose increases happen without you submitting anything
"Labs may be required" with no specifics	No labs ever — even when your symptoms or history call for them
No documented protocol for severe symptoms	You're told to "message us" if you have severe pain
Monthly cost looks suspiciously low	Locked into a 6- or 12-month contract
Limited nutrition or exercise guidance	"Just take the medication and don't worry about it"
Different provider every visit, no continuity	Compounded medication marketed as "the same as Ozempic"
Dosing instructions only in units, no mg	No pharmacy name disclosed for compounded products

The single most common quiet failure: dose increases that happen on a calendar, not based on tolerability. If your dose has gone up every interval since you started, and nobody’s asked you about side effects in detail, the system is running on autopilot.

Experiencing severe GI side effects right now?

Our GLP-1 sick day rules guide covers what to do when you’re vomiting or dehydrated, when to call, and when to go to the ER.

GLP-1 Sick Day Rules →

Special situations: when the standard follow-up isn’t enough

Some patients need extra follow-up because their risk profile is different. Diabetes medications, pregnancy planning, planned surgery, severe GI symptoms, kidney disease, certain thyroid history, and oral contraceptive use with tirzepatide all change what a safe visit should cover.

If you have diabetes

A safe follow-up reviews your glucose logs, asks about hypoglycemia symptoms (especially if you're on insulin or a sulfonylurea), checks vision changes (rapid blood sugar improvement can temporarily worsen diabetic retinopathy), and adjusts your other diabetes medications when appropriate. The Wegovy and Mounjaro labels both warn that hypoglycemia risk increases when GLP-1s are combined with insulin or sulfonylureas.

If you use oral birth control pills and you're on tirzepatide

The Zepbound label specifically advises that patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation. Why: tirzepatide's effect on stomach emptying can reduce the absorption of oral hormones. If your provider has never mentioned this, ask. Now.

If you're planning a pregnancy or might be pregnant

The Wegovy label says to stop Wegovy at least 2 months before a planned pregnancy. The Zepbound label says to discontinue when pregnancy is recognized and to tell your provider if pregnancy is planned or occurs during treatment. A safe follow-up asks about this — it's not nosy, it's standard.

If you have a surgery or procedure coming up

In October 2024, a coalition of professional societies (ASA, AGA, ASMBS, IPCO, SAGES) released updated guidance: most patients should continue GLP-1s before elective surgery. For patients at highest risk of GI complications, a 24-hour liquid diet before the procedure can help. Tell both your surgical team and your prescribing provider about any planned procedure at least a few weeks ahead.

If you have severe GI symptoms or signs of dehydration

Persistent vomiting, diarrhea, or inability to keep fluids down can lead to dehydration and acute kidney injury — and both the Mounjaro and Zepbound labels specifically mention kidney monitoring when volume depletion is a risk. A safe follow-up doesn't tell you to "ride it out." It asks how often, how severe, and whether you're getting enough fluid in.

If you have severe constipation

Severe constipation with belly pain, bloating, vomiting, or inability to pass stool or gas can be a sign of bowel obstruction, which is a surgical emergency. "Just drink more water" isn't the right response from your provider.

If you have thyroid history

If you or a close blood relative has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), GLP-1s and dual GIP/GLP-1 agonists are contraindicated — meaning don't use them, period. If your intake never asked, that's a serious gap.

On tirzepatide and oral contraceptives?

Our GLP-1 and oral contraceptives guide explains exactly which drugs need backup, when, and for how long — with a date calculator.

GLP-1 & Birth Control Guide →

The exact questions to ask your provider at your next visit

A safe follow-up should answer 15 specific questions. Save or screenshot this list. Send it to your provider’s portal before your next visit, or work through it on the call. The answers tell you whether your follow-up meets the bar — better than any review or rating ever will.

What's the full name and license number of the clinician handling my care?
Is my medication FDA-approved or compounded?
If compounded, what pharmacy is it from, and what's the concentration?
What's my exact dose in milligrams, and what does that translate to in units on my syringe?
Is my dose going up at the next refill, or are we holding? Why?
What side effects, specifically, would make you delay the next increase?
What symptoms should make me call you urgently — and what's the number?
What symptoms should send me to the ER?
Do I need labs based on my history, and which ones?
Are any of my current medications a concern with this one?
(If diabetic) Do my other diabetes medications need to be adjusted?
What should I do if I miss a dose? How many missed doses changes the answer?
What should I do if I have surgery or anesthesia coming up?
(If using oral birth control on tirzepatide) Do I need backup contraception, and for how long?
What's the plan if I want to stop, or if my supply is interrupted?

A safe program answers all 15 in plain English. If you get a templated answer, a non-answer, or “we’ll get back to you” on more than two or three of these, you have your answer about the program.

How to score your provider in 5 minutes

Tally one point for each element where you can answer “yes.” A score of 7–9 means your follow-up is solid. A score of 4–6 means specific gaps to ask about. A score of 3 or below means you’re missing the minimum safety checks.

Element	Yes if…
1. Identifiable, licensed prescriber	You can name your prescriber and find their license on your state board
2. Real clinical check-in (not just a form)	A real clinician has responded specifically to your situation in the past 60 days
3. Side-effect screen (pancreatitis, gallbladder, thyroid red flags)	Your provider has asked specifically about these — not just "any side effects"
4. Documented dose decision	The reason for your last dose change is written down and you can find it
5. Risk-based labs	You've had baseline labs, and the lab plan matches your risk (diabetes, GI symptoms, etc.)
6. Weight + body composition tracking	Trend is tracked; strength and protein have been discussed at least once
7. Lifestyle review	Protein, training, sleep, or mental health have come up at follow-up
8. Clear urgent-symptom protocol	You know exactly what to do for severe pain, allergy, or other urgent symptoms
9. Stop / pause / restart plan	You've discussed what happens if you stop or if supply is interrupted

7–9 points

Solid

Your follow-up meets the standard.

4–6 points

Gaps

Ask the questions above for whichever elements scored zero.

0–3 points

Missing minimums

Either push your provider hard or look at alternatives.

Honest tradeoffs: what this checklist isn’t

This is the floor, not the ceiling.

Patients with complex conditions — chronic kidney disease, prior pancreatitis, family MTC history, severe psychiatric history, eating disorder history, pregnancy planning — may need more than the minimum. The 9 elements describe a safe baseline.

Telehealth versus in-person isn't a value judgment.

It's a fit question. Some readers do better with a combination — telehealth for refills and routine check-ins, in-person obesity medicine specialists for periodic deep reviews.

We don't rank providers on this page.

On purpose. The scorecard works on any provider, including new ones that don't have reviews yet.

This isn't medical advice.

It's an editorial checklist built from FDA labels, major clinical practice guidelines (Endocrine Society, OMA, ADA, TOS, ACLM, ASN, ACC), telehealth prescribing rules, and FDA enforcement records. We're not your clinician. If you have an urgent symptom, follow the urgent-symptom protocol above and call your provider or 911.

What we actually verified

For this page, we independently reviewed: the current FDA/DailyMed labeling for Wegovy injection and tablets, Zepbound, Ozempic, Mounjaro, Rybelsus, and Saxenda; the FDA’s April 1, 2026 approval announcement for Foundayo (orforglipron) and its dosing schedule; FDA compounded-GLP-1 enforcement actions including the March 3, 2026 warning-letter announcement and the February 6, 2026 statement on enforcement escalation; Florida’s current obesity-medication rule (64B15-14.004); Mississippi’s published guidance; the 2025 joint nutritional advisory from the OMA, TOS, ASN, and ACLM; the Endocrine Society’s pharmacological obesity guideline; the ADA Standards of Care; the ACC’s 2025 Clinical Guidance on weight-management drugs; the October 2024 multi-society perioperative guidance; the November 2025 KFF Health Tracking Poll; and the 2025 JAMA Network Open cohort study on GLP-1 discontinuation.

Frequently Asked Questions

How often should I see my GLP-1 telehealth provider?

Every 2 to 4 weeks during the dose-changing phase (typically the first 16 to 24 weeks). Every 3 months at minimum once you're on a stable maintenance dose. Florida's current obesity-medication rule requires at least every 3 months. Other state rules can require more — check your state board directly.

What labs are needed during GLP-1 follow-up?

Labs are risk-based, not universal. The ADA's patient guidance says A1C is usually checked every 3 months if medications changed or you're not at your target, and every 6 months once at goal. A comprehensive metabolic panel becomes more important with severe GI symptoms or kidney concerns. TSH is not a screen for the GLP-1 boxed-warning thyroid C-cell tumor risk.

Is asynchronous follow-up safe for GLP-1?

It can be, when a real licensed clinician reviews your information, you have a path to a synchronous (video or phone) visit when needed, and there's a documented urgent-symptom protocol. An auto-approved form isn't safe — that's not asynchronous care, that's automation.

What questions should my doctor ask at a GLP-1 follow-up?

Specific GI symptoms and severity (nausea, vomiting, diarrhea, constipation, reflux). Red-flag symptoms (severe abdominal pain, right-upper-belly pain, lump in the neck, persistent hoarseness, vision changes). Missed doses. Other medications. Pregnancy or surgery plans. Weight trend. Protein intake and strength training. Hypoglycemia symptoms if you take insulin or sulfonylureas. Mental health.

When should I call my doctor between follow-ups?

Severe persistent abdominal pain (especially radiating to the back), right-upper-belly pain with fever or yellowing of the skin or eyes, a new neck mass or persistent hoarseness, an allergic reaction, persistent vomiting with inability to keep fluids down, severe constipation with belly distension and vomiting, signs of low blood sugar if you take insulin or sulfonylureas, or any new symptom that worries you. These FDA-labeled urgent symptoms shouldn't go in a portal message — use a phone, urgent care, or an ER depending on severity.

How do I know if my GLP-1 telehealth provider is legit?

Verify the prescriber's license on your state medical board portal. Confirm the platform requires real clinical review (not just an auto-approved form). Check for a documented urgent-symptom protocol. Use the 9-element scorecard above.

Will my follow-up change if I'm on compounded semaglutide or tirzepatide?

The 9-element standard is the same. Compounded therapy adds three follow-up jobs: confirming the pharmacy and concentration on every refill, checking dose instructions (especially when given in units rather than mg), and having a transition plan in case of supply or regulatory changes. The FDA has documented dosing errors specifically tied to unit-versus-mg confusion with compounded semaglutide.

Do I have to see someone in person eventually?

Not always — but you should have a clear path to in-person care if your condition becomes complex, if you develop a serious side effect, or if your state law requires it. Some patients do best with a hybrid setup: telehealth for routine follow-ups, in-person obesity medicine specialists for periodic deep reviews.

What if I'm on tirzepatide and use oral birth control pills?

The Zepbound label advises switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. This is because tirzepatide's effect on stomach emptying can reduce absorption of oral hormones. If your provider hasn't mentioned this, bring it up at your next visit.

What if I miss a GLP-1 dose?

Missed-dose instructions are medication-specific. For Wegovy injection, take the missed dose as soon as possible if the next scheduled dose is more than 2 days away; if less than 2 days away, skip and take the next dose on the regularly scheduled day. For Wegovy tablets, skip the missed dose and take the next dose the following day. For Zepbound, take the missed dose within 4 days; if more than 4 days have passed, skip it. Don't apply one drug's rule to another — confirm with your provider.

Sources

FDA-approved labeling (DailyMed)

Wegovy (semaglutide) injection and tablets — current label on DailyMed
Ozempic (semaglutide) — current label on DailyMed
Zepbound (tirzepatide) — current label on DailyMed
Mounjaro (tirzepatide) — current label on DailyMed
Rybelsus (oral semaglutide) — current label on DailyMed
Foundayo (orforglipron) — current label on DailyMed; FDA approval April 1, 2026

FDA enforcement and safety communications

FDA press release: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, March 3, 2026
FDA statement on compounded GLP-1 enforcement, February 6, 2026
FDA alerts on dosing errors with compounded injectable semaglutide

Clinical practice guidelines

American Diabetes Association — Standards of Care in Diabetes (current edition)
Endocrine Society — Pharmacological Management of Obesity guideline (5% at 3 months benchmark)
Obesity Medicine Association — Clinical Practice Statement on telehealth (2022)
American College of Cardiology — 2025 Clinical Guidance on Weight Management Drugs
Mozaffarian D et al., "Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA, and TOS," American Journal of Clinical Nutrition, 2025

Perioperative and telehealth standards

ASA / AGA / ASMBS / IPCO / SAGES — Multi-society guidance on GLP-1 medications and elective surgery, October 2024
American Telemedicine Association — Asynchronous Healthcare Definitions and Use Cases
HHS — Telehealth informed consent guidance

State rules (verified May 2026)

Florida Administrative Code Rule 64B15-14.004 — Standards for the Prescription of Drugs to Treat Obesity
Mississippi Board of Medical Licensure published guidance on off-label weight-loss prescribing
Virginia: Rule 18VAC85-50-181 marked repealed effective July 17, 2025

Population and outcomes data

KFF Health Tracking Poll, November 2025 — GLP-1 use prevalence (~1 in 8 U.S. adults currently taking)
JAMA Network Open, 2025 — Cohort study of 125,474 adults on GLP-1 discontinuation and reinitiation
Acta Diabetologica — "Muscle loss and GLP-1R agonists use," 2025
American Journal of Medicine — "Sarcopenia in the era of GLP-1 receptor agonists," February 2026

Update Log

Date	Change	Why
2026-05-18	Initial publication.	Page created.

Next scheduled review: August 2026. Faster updates as new FDA enforcement actions or label revisions are published.

Last updated: May 18, 2026 · Last verified: May 18, 2026

This page was written by the WPG Editorial Team using FDA-approved drug labels (DailyMed), clinical practice guidelines from the major medical societies named in sources, state medical board rules verified in May 2026, and FDA enforcement records from September 2025 through May 2026. We don’t accept payment in exchange for inclusion or positive coverage of any specific telehealth provider on this page. This page is not medical advice. If you have urgent symptoms, contact your provider or call 911.